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Management of Chronic Staphylococcal Osteomyelitis of the 
Temporal Bone: The Use of Hyperbaric Oxygen 
Vanessa G. Schweitzer, MD* 
Hyperbaric oxygen (HBO) is an effective adjunct in the managemeni of selected otolaryngologic 
problems including radiation-induced necrosis of the temporal hone, malignant external otitis, 
mandibular osteoradionecrosis and refractory osteomyelitis, soft tissue head and neck necrotizing 
fasciitis, compromised skin flaps and grafts, acute air or gas embolism, and otologic barotrauma. We 
describe the management of a patient with insidious Staphylococcus aureus osteomyelitis of the 
temporal bone by the use of HBO preoperatively and postoperatively in conjunction with surgical 
debridement. The possible application of angiogenic agents and tetracycline hone-labeling in 
combination with HBO therapy in the management of refractory neurotologic disease is discussed. 
(Henry Ford Hosp MedJ 1990:38:16-20) 
In the past 15 years many studies have reported the application of hyperbaric oxygen (HBO) as an adjunct to the treatment of 
radiation-induced necrosis of the temporal bone, malignant ex-
temal otitis, mandibular osteoradionecrosis and refractory os-
teomyelitis, soft tissue head and neck necrotizing fasciitis, com-
promised skin flaps and grafts, and acute air or gas embolism. 
The use of HBO has atso been investigated in the treatment of 
sudden sensorineural hearing loss, tinnitus, and vertigo sec-
ondary to acute otologic hypoxia and barotrauma (1-13). Infor-
mation regarding the indications for HBO therapy, its mecha-
nisms of action, and details of treatment protocol have been doc-
umented under the auspices of the Hyperbaric Oxygen Commit-
tee of the Undersea Medical Society (14,15), 
Conditions for which HBO is accepted as indicated therapy 
are listed in Table 1, Mandatory rules for HBO administration 
include; 1) abstinence of smoking during the entire course of 
therapy; 2) avoidance of flammable synthetic clothing (ie, ny-
lon); 3) avoidance of flammable topical materials, such as petro-
leum jelly, glycerin, lanolin products, hair spray, oils, tonic, 
wigs, mustache wax, cosmetics, cologne, or perfume; 4) pa-
tients must avoid gum or candy because of the risk of seizures; 
and 5) flammable reading materiat may not be brought into the 
chamber. Certain drugs and medical conditions which may has-
ten or delay the onset of HBO toxicity should be considered in 
the selection of patients (Tables 2 and 3), 
Side effects of HBO therapy are the resutt of hyperoxygena-
tion and barotrauma. These inctude transient reversible myopia, 
maturation ofexisting cataracts, seizures, nitrogen narcosis, and 
the adult respiratory distress syndrome or pulmonary fibrosis 
which are caused by hyperoxygenation. Pressure-related side 
effects inctude eustachian tube dysfunction, otologic baro-
trauma, sinus "squeeze," pneumothorax and/or pneumomedi-
astinum, gastrointestinal gas expansion, arterial gas emboli, and 
decompression sickness. With appropriate patient screening and 
education, the incidence of these complications is minimal (15), 
The beneficial effects of HBO therapy are the result of; 1) hy-
peroxygenation of tissues, hemoglobin, and plasma; 2) vaso-
constriction without hypoxia which reduces tissue edema, com-
partment pressure, and intracranial pressure; 3) pressure effects 
which reduce gas bubble size; and 4) antimicrobial activity from 
enhanced leukocytic bactericidal activity and reduced produc-
tion of toxins in soft tissue. A secondary effect of HBO therapy 
is enhanced wound heating because of fibroblast proliferation, 
improved osteoclastic function, and increased red blood cell de-
formabitity. 
Pretherapy evaluation should include a chest x-ray and spi-
rometry to rute out chronic obstructive pulmonary disease, 
blebs, and bullae, as wett as a careful search for optic neuritis 
and cataracts. Claustrophobia and morbid obesity may preclude 
treatment depending on the type of chamber and method of ox-
ygen administration. 
The foltowing report illustrates the management of an unusu-
al case of Staphylococcus aureus osteomyelitis of the temporal 
bone which was secondary to cholesteatoma and chronic mas-
toiditis. 
Case Report 
Since childhood this 48-year-old woman had chronic tympanic 
membrane perforation wilh suppurative otitis media of the righl ear. 
Fifteen years earlier she had been seen for granulomatous mastoiditis, 
otorrhea, and middle ear cholesteatoma. Cultures of middle ear drain-
age grew Staphylococcus aureus and Pseudomonas aeruginosa. Her 
morbid obesity and endomorphic habitus limited access to her veins 
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Table I 
Accepted Indications for Use 
of Hyperbaric Oxygen Therapy 
Table 2 
Factors Hastening Hyperbaric Oxygen Toxicity 
1. Radiation necrosis: Osteoradionecrosis: soft tissue radionecrosis 
2. Refractory osteomyelitis 
3. Refractory mycoses 
4. Necrotizing and mixed soft tissue infections 
5. Gas gangrene (Clostridial) 
6. Compromised skin grafts or flaps 
7. Healing enhancement in selective problem wounds 
8. Acute traumatic ischemia (crush injuries) 
9. Decompression sickness 
10. CO, and cyanide poisoning; smoke inhalation 
11. Arterial gas (air) embolism 
12. Acute cerebral edema 
13. Special consideration: thermal bums; acute anemia 
and made either computed tomography (CT) or magnetic resonance 
imaging (MRI) very difficult. She had a 304- pack/year smoking history 
and multiple topical and systemic drug allergies and idiosyncratic sen-
sitivities. 
The patient's condition worsened progressively over this 15-year pe-
riod. Foul otorrhea was associated with spiking fevers (40° C [104° F), 
cellulitis and diffuse swelling overthe temporal, parietal, and infraorbi-
tal areas, wilh woody induration ofthe auricle, and obliterative mastoid 
granulation. Deep pain persisted in the temporal, postauricular, and ret-
ro-orbital regions. Intermittent right facial twitching correlated with 
surgically documented intralabyrinthine and vertical facial nerve de-
hiscence (Figs IA and IB), Despite multiple surgical procedures and 
long-term antibiotic therapy, mastoid biopsies consistently demon-
strated necrotic and hypertrophic mucosa, cholesteatoma, and fibro-
blastic proliferation. Granuloma formation was secondary to powdered 
chloramphenicol crystals. Cultures demonstrated methicillin-resistant 
Staphylococcus aureus, Pseudomonas aeruginosa, and Bacteroides 
melaninogenicus. Antibiotic treatment, all of which failed, included 
imipenem and vancomycin, imipenem and gentamicin, cefazolin sodi-
um, and ciprofloxacin. 
Systemic candidiasis, Clostridia difficile gastroenteritis, catheter-in-
duced Staphylococcus aureus septicemia, cephalic vein thrombophleb-
itis, vancomycin-induced "red neck syndrome," and gentamycin-in-
duced oscillopsia and ataxia all occurred, as complications of the long-
term medical therapy. 
Over a ten-year period the patient had ten surgical procedures, in-
cluding tympanoplasty, extended radical mastoidectomy, temporal cra-
niectomy with intradural pericranial graft, partial petrous apicectomy, 
facial nerve decompression, and mastoid cavity fat obliteration. CT of 
the right temporal bone demonstrated marked irregularity of the anteri-
or wall ofthe right extemal auditory canal, highly suggestive of chronic 
osteomyelitis. CT also demonstrated dehiscence of the right legmen 
lympani and lateral aspect of the petrous ridge, opacification of the 
mastoid, and early inflammatory changes in the right cerebellum sug-
gesting an evolving intracranial abscess (Figs 2A and 28). 
Because conventional medical and surgical management had failed, 
the patient was referred for adjunct HBO therapy. After preoperative 
bone-labeling with tetracycline, the patient underwent extended radical 
revision mastoidectomy and split-thickness skin graft of the cavity. 
"Leathery" granulomatous tissue and osteitic bone were removed from 
the middle ear, eustachian tubal orifice, anterior bony canal wall, and 
facial ridge. Postoperatively, the patient received 20 outpatient HBO 
treatments (90 minutes daily at 2.4 atmospheres of absolute pressure 
[ATA]). After only len HBO treatments, high-resolution CT demon-
Adrenocortical steroids Dextroamphetamine 
COj inhalation Epinephrine 
Vitamin E deficiency Norepinephrine 
Hyperthyroidism Insulin 
Hyperthermia Diamox 
Narcotic agents 
Table 3 
Factors Delaying Onset of Hyperbaric Oxygen Toxicity 
Adrenergic blocking dmgs Intermittent Oj exposure 
Antioxidants Hypothyroidism 
Chlorpromazine Starvation 
Anticonvulsants Hypothermia 
Ganglionic blocking drugs Acclimation to hypoxia 
Glutathione Reserpine 
Gamma-aminobutyric acid Succinate 
Disulfiram Trisaminomethane 
strated marked improvement in the irregularity of the extemal auditory 
canal wall and better definition of the petrous bone (Fig 2C). The deep 
pain, granulation tissue, and cellulitis resolved (Fig 3). The Westergren 
sedimentation rate retumed to near normal (29 mm/hr from 83 mm/hr). 
No evidence of temporal bone osteomyelitis persists one and a half 
years later. The patient wears a right bone conduction hearing aid. Her 
ataxia and oscillopsia have markedly improved, and she is ambulatory 
and capable of light work. 
Discussion 
Previous otolaryngologic reports have stressed the impor-
tance of combined antibiotic treatment and adjunct HBO thera-
py for treatment of radiation-induced osteomyelitis, osteoradio-
necrosis, and Pseudomonas "malignant" or necrotizing extemal 
otitis of the temporal bone (16-24). The present case suggests 
that HBO therapy is atso effective in the adjunct management of 
chronic osteomyelitis of the temporal bone, which occurred as a 
complication of cholesteatoma and otomastoiditis. 
Assessment of chronic osteomyelitis of the temporal bone 
must include detection of host compromising factors. Such 
evaluation requires sequential radiologic imaging with CT and 
radionuclide bone and soft tissue scintigraphy. Antibiotic ther-
apy must be culture-directed ana prolonged. 
Waming signals suggesting devetopment of chronic osteitis/ 
osteomyelitis ofthe temporal bone include deep pain (temporal, 
parietal, postauricular, retro-orbital), intermittent foul otorrhea 
with spiking fevers, periauricular cellulitis, woody induration of 
the pinna, chronic mastoid-cutaneous fistula, fibrotic mastoid 
granulation tissue, intermittent facial twitching suggestive of fa-
cial canal dehiscence, and persistent leukocytosis with etevated 
sedimentation rate. Impending (neur)otologic complication 
may be signaled by the foltowing: 1) acute exacerbation of pum-
tent, malodorous drainage often preceded by headache or otal-
gia; 2) low-grade or spiking fever; 3) systemic symptoms, such 
as lethargy, emesis, blurred vision, altered mental status, apha-
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Fig 1 (A and B)—Staphylococcus aureus osteomyelitis ofthe right temporal bone secondaiy to chronic suppurative otitis media with 
cholesteatoma. Cellulitis and swelling over the temporal and infraorbital regions. Rubbery, odiferous mastoid granulation tissue. 
Woody edema ofthe auricle. Spiking fevers (40° C) associated with sedimentation rate four times normal. 
Fig 2 A—Pre HBO therapy; high-resolution CT of the right tem-
poral bone (coronal view). Erosion of anterior bony watt of ex-
ternal auditory canal. Opacification ofthe mastoid cavity. 
Fig 2B—Pre HBO therapy; high-resolution CT (axial view). 
Evolving abscess ofthe right cerebellum. 
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Fig 2C—Post HBO therapy; high-resolution CT after extended 
radical mastoidectomy. split-thickness skin graft ofthe tempo-
ral bone defect, ten of 20 HBO treatments, and oral cip-
rofloxacin. Less bone irregularity of anterior exiernal auditory 
canal wall. 
sia, and mental confusion; and 4) otologic complications, such 
as auricular cellulitis, suppurative labyrinthitis, and subperios-
teal abscess (25), 
The diagnosis of osteoradionecrosis, osteomyelitis, and ma-
lignant extemal otitis is primarily "clinical." Radiologic studies 
may demonstrate inflammatory disease of the temporal bone but 
often lag behind the severe early clinical signs. Radiologic bone 
changes demonstrating bone lysis and dissolution appear slowly 
even in acute osteolytic osteomyelitis. Bone imaging is not di-
agnostic until 30% to 50% of bone is lost (20). The three most 
reliable procedures for diagnosis and evaluation ofthe progress 
of chronic temporal bone inflammation are thin section, high-
resolution CT in combination with gallium-67 citrate and 
triphasic '''^ "'technetium-Iabeled phosphate anion bone scintigra-
phy (18-22,26). Gallium scanning demonstrates the nonspecific 
binding of gallium to actively dividing cells and organelles (leu-
kocytes, tumor cells, actively dividing osteoblasts) in soft tissue 
inflammation. The procedure reveals osteogenic activity from 
the stage of initial infection through phases of healing, persis-
tence, or recurrence, indicating the degree of therapeutic re-
sponse 99mjj, (jQpg imaging demonstrates acute osteitis and os-
teomyelitis and is used to differentiate "healing" from active in-
fection. Technetium scans can detect morphologic findings be-
fore structural changes are seen on CT and may reveal physio-
logic changes in advance of the healing process. Gallium scan 
findings improve or become normal when the infecfion is steril-
ized, while the technetium scan remains abnormal and indicates 
the extent of bone destmction. 
Antimicrobial therapy is selected on the basis of cultures and 
antibiotic sensitivity. Ideally, antibiotic therapy should inctude 
Fig 3—Operative site fotlowing 20 HBO treatments. Com-
pletely epithelialized mastoid defect. Heated postauricular 
mastoid-cutaneous fistula. No granulation tissue. Fever, pain, 
and abnormal sedimentation rate now resolved. 
an aminoglycoside plus an anti-Pseudomonal penicillin, a fluo-
roquinolone, or a carbapem. 
Whenever possible, surgical management of chronic os-
teomyelitis of the temporal bone should be performed after pre-
operative tetracycline labeling. Operative plans include consid-
eration of limited versus radical removal of nonviable bone, as 
well as postoperafive management of the mastoid cavity. Tetra-
cycline, 250 mg orally four times daily, is administered for 
seven to ten days prior to surgery. Use of ultraviolet light in-
traoperatively produces fluorescence of the viable bone and fa-
cilitates surgical removal of diseased tissue (10,16). Managing 
the residual mastoid cavity is a difficult problem, particularly 
when granulation tissue, drainage, and pain persist. Optimal 
healing may require obliteration of the cavity with abdominal 
fat, a rotational flap, or split-thickness skin graft. 
HBO has been effective in treating experimentally-induced 
staphylococcal osteomyelitis in rabbit tibia (27). Compared to 
normal bone, osteomyelific bone has decreased blood flow and 
markedly reduced partial pressure of oxygen. Reduced tissue 
oxygen impairs phagocytic and/or intracellular killing mecha-
nisms (27). 
The three variables of HBO therapy in the management of 
chronic osteomyelitis of the temporal bone are; 1) correlation 
with medical and surgical intervention, 2) duration of treatments 
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which is determined by clinical response and radiologic chang-
es, and 3) frequency of "dives." Clinical response to HBO ther-
apy is indicated by relief of pain, subsidence of otorrhea and fe-
ver, and fait to normal in the sedimentation rate. Resolution of 
pathological bone imaging and no further devetopment of mas-
toid granulations six months fotlowing HBO therapy are evi-
dence of remission. Although the absolute pressure used, the 
number of days, and frequency of HBO treatments may vary, 
standard treatment is usually conducted at 2.5 ATA (45 feet be-
tow sea level) for 90 to 120 minutes, one or two times daily. This 
schedule for high-dose, short-term, and intermittent 100% oxy-
gen administration minimizes oxygen toxicity (2,4,15). 
New experimental pharmacologic agents (in combination 
with medical, surgical, and HBO therapy) may prove effective 
in hastening wound healing by improving tissue oxygenation 
and stimulating neovascularization. Such pharmacologic agents 
inctude endothelial growth factors, free radical scavengers, and 
the recentiy reported methytxanthines. The methylxanthine, 
pentoxifylline, decreases blood viscosity, increases red blood 
celt deformabitity, and improves red blood cett flow properties. 
In combination with HBO therapy the agent has been shown to 
enhance flap survival in rats (28,29). Two types of angiogenic 
factors have been reported to enhance skin flap neovasculariza-
tion when applied topically or when impregnated in Gelfoam 
carriers for sustained release; 1) endothelial growth supptement, 
a neural extract from bovine hypothalamus which is mitogenic 
to endothelial celts; and 2) endothelial growth cell factor, an 
acidic polypeptide from bovine neural tissue which induces en-
dothelial cell replicafion (30). Certain free radical scavengers 
have been demonstrated to reduce flap ischemia and to delay the 
onset of HBO toxicity. These include superoxide dismutase, al-
lopurinol, vitamin E, glutathione, and disulfiram (31), Future 
management of inflammatory disease of the head and neck may 
wett involve the use of HBO in combinafion with such pharma-
cologic agents. 
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